Sarepta Ready To Move Higher By Efs Investments
November 19, 2012 Sarepta has a wonderful drug in its pipeline, which can dominate the market for years. Unlike many other drugs, Eteplirsen has support from the public who want this drug to be in the market. It has shown phenomenal results and may force the FDA to approve the drug without phase III trials. Regardless of early approval, the stock will continue to move up in the short and medium term. However, if the early approval is granted - the stock will move up rapidly. In addition, it is extremely unlikely that the company will face competition any time soon. I remain particularly optimistic and confident that Sarepta will provide massive returns to investors.
Sentiment: Strong Buy